[{"edinetCode":"E00935","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1405.0,"averageTemporaryStaff":298.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":12742000.0,"sharesOwendPercent":0.2631,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":2511.68,"equityRatio":0.76,"cashAndCashEquivalents":43767000000.0,"assets":135060000000.0,"currentAssets":90494000000.0,"fixedAsset":44565000000.0,"tangibleFixedAssets":26271000000.0,"intangibleFixedAssets":372000000.0,"investmentAndOtherAssets":17921000000.0,"liabilities":32405000000.0,"currentLiabilities":24020000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":8384000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":102655000000.0,"capitalStock":99778000000.0,"capital":23853000000.0,"capitalSurplus":11407000000.0,"accumulatedEarnings":84331000000.0,"treasuryStock":-19813000000.0,"valuationAndConversionAdjustments":2876000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":101479000000.0,"costOfSales":44539000000.0,"grossProfit":56940000000.0,"sgaExpenses":26745000000.0,"salaryAndBenefit":null,"depreciationAndSGA":275000000.0,"RDExpenses":6450000000.0,"operatingIncome":30707000000.0,"nonOperatingIncome":343000000.0,"nonOperatingExpenses":69000000.0,"interestExpense":21000000.0,"ordinaryProfit":30981000000.0,"extraordinaryGain":252000000.0,"extraordinaryLoss":142000000.0,"incomeBeforeTax":31092000000.0,"incomeTaxes":9075000000.0,"netIncome":22017000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":22017000000.0,"comprehensiveIncome":22587000000.0,"eps":536.7,"dilutedEps":null,"dividendPerShare":null,"per":11.7,"roe":0.229,"cashFlowFromOperatingActivities":15327000000.0,"depreciationAndCashflowFromOperatingActivities":1937000000.0,"cashFlowFromInvestingActivities":-3503000000.0,"cashFlowFromFinancialActivities":-9800000000.0,"changesInCashAndCashEquivalents":2023000000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4521,"accountingYear":"第97期(自　平成28年４月１日　至　平成29年３月31日)","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1389.0,"averageTemporaryStaff":284.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13457000.0,"sharesOwendPercent":0.3338,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":2824.32,"equityRatio":0.747,"cashAndCashEquivalents":52694000000.0,"assets":152417000000.0,"currentAssets":105055000000.0,"fixedAsset":47362000000.0,"tangibleFixedAssets":26141000000.0,"intangibleFixedAssets":552000000.0,"investmentAndOtherAssets":20668000000.0,"liabilities":38543000000.0,"currentLiabilities":31401000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7141000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":113874000000.0,"capitalStock":109287000000.0,"capital":23853000000.0,"capitalSurplus":11408000000.0,"accumulatedEarnings":97284000000.0,"treasuryStock":-23259000000.0,"valuationAndConversionAdjustments":4587000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":98430000000.0,"costOfSales":42405000000.0,"grossProfit":56024000000.0,"sgaExpenses":28530000000.0,"salaryAndBenefit":null,"depreciationAndSGA":204000000.0,"RDExpenses":8152000000.0,"operatingIncome":27496000000.0,"nonOperatingIncome":412000000.0,"nonOperatingExpenses":53000000.0,"interestExpense":16000000.0,"ordinaryProfit":27854000000.0,"extraordinaryGain":null,"extraordinaryLoss":168000000.0,"incomeBeforeTax":27686000000.0,"incomeTaxes":8643000000.0,"netIncome":19043000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":19043000000.0,"comprehensiveIncome":20753000000.0,"eps":470.54,"dilutedEps":null,"dividendPerShare":null,"per":13.3,"roe":0.176,"cashFlowFromOperatingActivities":21703000000.0,"depreciationAndCashflowFromOperatingActivities":2124000000.0,"cashFlowFromInvestingActivities":-3245000000.0,"cashFlowFromFinancialActivities":-9530000000.0,"changesInCashAndCashEquivalents":8927000000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4521,"accountingYear":"第98期(自　平成29年４月１日　至　平成30年３月31日)","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1341.0,"averageTemporaryStaff":262.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13680000.0,"sharesOwendPercent":0.3444,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":3049.78,"equityRatio":0.777,"cashAndCashEquivalents":58555000000.0,"assets":155985000000.0,"currentAssets":103731000000.0,"fixedAsset":52254000000.0,"tangibleFixedAssets":26402000000.0,"intangibleFixedAssets":551000000.0,"investmentAndOtherAssets":25299000000.0,"liabilities":34854000000.0,"currentLiabilities":27580000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7274000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":121131000000.0,"capitalStock":117536000000.0,"capital":23853000000.0,"capitalSurplus":11408000000.0,"accumulatedEarnings":109057000000.0,"treasuryStock":-26782000000.0,"valuationAndConversionAdjustments":3594000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":94165000000.0,"costOfSales":40366000000.0,"grossProfit":53799000000.0,"sgaExpenses":29209000000.0,"salaryAndBenefit":null,"depreciationAndSGA":224000000.0,"RDExpenses":10261000000.0,"operatingIncome":24592000000.0,"nonOperatingIncome":464000000.0,"nonOperatingExpenses":84000000.0,"interestExpense":17000000.0,"ordinaryProfit":24972000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":49000000.0,"incomeBeforeTax":24922000000.0,"incomeTaxes":7147000000.0,"netIncome":17775000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":17775000000.0,"comprehensiveIncome":16782000000.0,"eps":445.78,"dilutedEps":null,"dividendPerShare":null,"per":11.3,"roe":0.151,"cashFlowFromOperatingActivities":21129000000.0,"depreciationAndCashflowFromOperatingActivities":2153000000.0,"cashFlowFromInvestingActivities":-5744000000.0,"cashFlowFromFinancialActivities":-9524000000.0,"changesInCashAndCashEquivalents":5860000000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4521,"accountingYear":"第99期(自　2018年４月１日　至　2019年３月31日)","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.776,"cashAndCashEquivalents":null,"assets":155505000000.0,"currentAssets":104015000000.0,"fixedAsset":51489000000.0,"tangibleFixedAssets":26149000000.0,"intangibleFixedAssets":473000000.0,"investmentAndOtherAssets":24865000000.0,"liabilities":34900000000.0,"currentLiabilities":27740000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7159000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":120604000000.0,"capitalStock":117304000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":103156000000.0,"treasuryStock":-21112000000.0,"valuationAndConversionAdjustments":3299000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":22335000000.0,"costOfSales":9507000000.0,"grossProfit":12828000000.0,"sgaExpenses":6122000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1609000000.0,"operatingIncome":6705000000.0,"nonOperatingIncome":216000000.0,"nonOperatingExpenses":23000000.0,"interestExpense":4000000.0,"ordinaryProfit":6898000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":13000000.0,"incomeBeforeTax":6885000000.0,"incomeTaxes":2058000000.0,"netIncome":4826000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":4826000000.0,"comprehensiveIncome":4532000000.0,"eps":121.65,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4521,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13279000.0,"sharesOwendPercent":0.3412,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.797,"cashAndCashEquivalents":65469000000.0,"assets":154490000000.0,"currentAssets":103025000000.0,"fixedAsset":51465000000.0,"tangibleFixedAssets":26133000000.0,"intangibleFixedAssets":464000000.0,"investmentAndOtherAssets":24867000000.0,"liabilities":31307000000.0,"currentLiabilities":24176000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7131000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":123183000000.0,"capitalStock":119856000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":107877000000.0,"treasuryStock":-23281000000.0,"valuationAndConversionAdjustments":3326000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":45170000000.0,"costOfSales":19279000000.0,"grossProfit":25891000000.0,"sgaExpenses":12147000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":3334000000.0,"operatingIncome":13744000000.0,"nonOperatingIncome":259000000.0,"nonOperatingExpenses":74000000.0,"interestExpense":8000000.0,"ordinaryProfit":13929000000.0,"extraordinaryGain":1000000.0,"extraordinaryLoss":307000000.0,"incomeBeforeTax":13623000000.0,"incomeTaxes":4075000000.0,"netIncome":9547000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":9547000000.0,"comprehensiveIncome":9279000000.0,"eps":242.56,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":15657000000.0,"depreciationAndCashflowFromOperatingActivities":1132000000.0,"cashFlowFromInvestingActivities":-1517000000.0,"cashFlowFromFinancialActivities":-7226000000.0,"changesInCashAndCashEquivalents":6913000000.0,"列1":"q2r","submitDate":"2019\/11\/13","stockCode":4521,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.789,"cashAndCashEquivalents":null,"assets":160550000000.0,"currentAssets":109227000000.0,"fixedAsset":51322000000.0,"tangibleFixedAssets":25732000000.0,"intangibleFixedAssets":444000000.0,"investmentAndOtherAssets":25145000000.0,"liabilities":33864000000.0,"currentLiabilities":26823000000.0,"shorTermDept":3875000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7041000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":126685000000.0,"capitalStock":122942000000.0,"capital":23853000000.0,"capitalSurplus":11495000000.0,"accumulatedEarnings":110966000000.0,"treasuryStock":-23372000000.0,"valuationAndConversionAdjustments":3742000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":70178000000.0,"costOfSales":29852000000.0,"grossProfit":40325000000.0,"sgaExpenses":17893000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4741000000.0,"operatingIncome":22432000000.0,"nonOperatingIncome":481000000.0,"nonOperatingExpenses":85000000.0,"interestExpense":13000000.0,"ordinaryProfit":22829000000.0,"extraordinaryGain":4000000.0,"extraordinaryLoss":651000000.0,"incomeBeforeTax":22182000000.0,"incomeTaxes":6627000000.0,"netIncome":15554000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":15554000000.0,"comprehensiveIncome":15703000000.0,"eps":396.67,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/13","stockCode":4521,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1268.0,"averageTemporaryStaff":242.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13395000.0,"sharesOwendPercent":0.3438,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":3301.09,"equityRatio":0.814,"cashAndCashEquivalents":73322000000.0,"assets":157875000000.0,"currentAssets":108336000000.0,"fixedAsset":49538000000.0,"tangibleFixedAssets":25518000000.0,"intangibleFixedAssets":414000000.0,"investmentAndOtherAssets":23605000000.0,"liabilities":29406000000.0,"currentLiabilities":21655000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7750000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":128468000000.0,"capitalStock":126756000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":114869000000.0,"treasuryStock":-23373000000.0,"valuationAndConversionAdjustments":1712000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":89232000000.0,"costOfSales":38753000000.0,"grossProfit":50478000000.0,"sgaExpenses":23969000000.0,"salaryAndBenefit":null,"depreciationAndSGA":231000000.0,"RDExpenses":6418000000.0,"operatingIncome":26512000000.0,"nonOperatingIncome":549000000.0,"nonOperatingExpenses":114000000.0,"interestExpense":17000000.0,"ordinaryProfit":26946000000.0,"extraordinaryGain":7000000.0,"extraordinaryLoss":362000000.0,"incomeBeforeTax":26592000000.0,"incomeTaxes":7222000000.0,"netIncome":19370000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":19370000000.0,"comprehensiveIncome":17487000000.0,"eps":494.89,"dilutedEps":null,"dividendPerShare":null,"per":10.2,"roe":0.155,"cashFlowFromOperatingActivities":27468000000.0,"depreciationAndCashflowFromOperatingActivities":2312000000.0,"cashFlowFromInvestingActivities":-2528000000.0,"cashFlowFromFinancialActivities":-10173000000.0,"changesInCashAndCashEquivalents":14766000000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4521,"accountingYear":"第100期(自　2019年４月１日　至　2020年３月31日)","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.82,"cashAndCashEquivalents":null,"assets":158346000000.0,"currentAssets":108632000000.0,"fixedAsset":49714000000.0,"tangibleFixedAssets":25051000000.0,"intangibleFixedAssets":398000000.0,"investmentAndOtherAssets":24263000000.0,"liabilities":28518000000.0,"currentLiabilities":20722000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7796000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":129828000000.0,"capitalStock":127367000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":115768000000.0,"treasuryStock":-23661000000.0,"valuationAndConversionAdjustments":2460000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":18070000000.0,"costOfSales":7682000000.0,"grossProfit":10387000000.0,"sgaExpenses":5356000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1573000000.0,"operatingIncome":5031000000.0,"nonOperatingIncome":228000000.0,"nonOperatingExpenses":9000000.0,"interestExpense":4000000.0,"ordinaryProfit":5249000000.0,"extraordinaryGain":243000000.0,"extraordinaryLoss":7000000.0,"incomeBeforeTax":5485000000.0,"incomeTaxes":1664000000.0,"netIncome":3820000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3820000000.0,"comprehensiveIncome":4569000000.0,"eps":98.18,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/12","stockCode":4521,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13904000.0,"sharesOwendPercent":0.3608,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.817,"cashAndCashEquivalents":74666000000.0,"assets":161039000000.0,"currentAssets":110939000000.0,"fixedAsset":50099000000.0,"tangibleFixedAssets":25370000000.0,"intangibleFixedAssets":467000000.0,"investmentAndOtherAssets":24261000000.0,"liabilities":29486000000.0,"currentLiabilities":21837000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7649000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":131552000000.0,"capitalStock":128931000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":119174000000.0,"treasuryStock":-25503000000.0,"valuationAndConversionAdjustments":2621000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":36789000000.0,"costOfSales":15899000000.0,"grossProfit":20889000000.0,"sgaExpenses":11107000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":3267000000.0,"operatingIncome":9782000000.0,"nonOperatingIncome":249000000.0,"nonOperatingExpenses":22000000.0,"interestExpense":8000000.0,"ordinaryProfit":10010000000.0,"extraordinaryGain":378000000.0,"extraordinaryLoss":23000000.0,"incomeBeforeTax":10365000000.0,"incomeTaxes":3138000000.0,"netIncome":7226000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":7226000000.0,"comprehensiveIncome":8135000000.0,"eps":186.15,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":6691000000.0,"depreciationAndCashflowFromOperatingActivities":1130000000.0,"cashFlowFromInvestingActivities":-288000000.0,"cashFlowFromFinancialActivities":-5059000000.0,"changesInCashAndCashEquivalents":1344000000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4521,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2020\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.822,"cashAndCashEquivalents":null,"assets":160627000000.0,"currentAssets":110354000000.0,"fixedAsset":50273000000.0,"tangibleFixedAssets":25025000000.0,"intangibleFixedAssets":704000000.0,"investmentAndOtherAssets":24543000000.0,"liabilities":28643000000.0,"currentLiabilities":21039000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":7604000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":131983000000.0,"capitalStock":128948000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":119991000000.0,"treasuryStock":-26303000000.0,"valuationAndConversionAdjustments":3035000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":57082000000.0,"costOfSales":25280000000.0,"grossProfit":31802000000.0,"sgaExpenses":16853000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4862000000.0,"operatingIncome":14949000000.0,"nonOperatingIncome":439000000.0,"nonOperatingExpenses":40000000.0,"interestExpense":12000000.0,"ordinaryProfit":15347000000.0,"extraordinaryGain":379000000.0,"extraordinaryLoss":44000000.0,"incomeBeforeTax":15682000000.0,"incomeTaxes":4748000000.0,"netIncome":10934000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10934000000.0,"comprehensiveIncome":12256000000.0,"eps":282.69,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/2\/10","stockCode":4521,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2021\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":1215.0,"averageTemporaryStaff":225.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":13740000.0,"sharesOwendPercent":0.3582,"outstandingShares":null,"numberOfSubsidiary":1.0,"bps":3555.93,"equityRatio":0.834,"cashAndCashEquivalents":77305000000.0,"assets":163332000000.0,"currentAssets":113662000000.0,"fixedAsset":49669000000.0,"tangibleFixedAssets":25020000000.0,"intangibleFixedAssets":625000000.0,"investmentAndOtherAssets":24024000000.0,"liabilities":27074000000.0,"currentLiabilities":21276000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5798000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":136257000000.0,"capitalStock":131418000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":122462000000.0,"treasuryStock":-26304000000.0,"valuationAndConversionAdjustments":4839000000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":74979000000.0,"costOfSales":34073000000.0,"grossProfit":40906000000.0,"sgaExpenses":23118000000.0,"salaryAndBenefit":null,"depreciationAndSGA":227000000.0,"RDExpenses":6736000000.0,"operatingIncome":17788000000.0,"nonOperatingIncome":484000000.0,"nonOperatingExpenses":50000000.0,"interestExpense":17000000.0,"ordinaryProfit":18222000000.0,"extraordinaryGain":495000000.0,"extraordinaryLoss":59000000.0,"incomeBeforeTax":18657000000.0,"incomeTaxes":5252000000.0,"netIncome":13405000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":13405000000.0,"comprehensiveIncome":16532000000.0,"eps":347.37,"dilutedEps":null,"dividendPerShare":null,"per":12.5,"roe":0.101,"cashFlowFromOperatingActivities":14380000000.0,"depreciationAndCashflowFromOperatingActivities":2318000000.0,"cashFlowFromInvestingActivities":-1644000000.0,"cashFlowFromFinancialActivities":-8752000000.0,"changesInCashAndCashEquivalents":3983000000.0,"列1":"asr","submitDate":"2021\/6\/29","stockCode":4521,"accountingYear":"第101期(自　2020年４月１日　至　2021年３月31日)","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2021\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.831,"cashAndCashEquivalents":null,"assets":163340000000.0,"currentAssets":112651000000.0,"fixedAsset":50689000000.0,"tangibleFixedAssets":25772000000.0,"intangibleFixedAssets":648000000.0,"investmentAndOtherAssets":24267000000.0,"liabilities":27640000000.0,"currentLiabilities":21592000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":6048000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":135699000000.0,"capitalStock":130925000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":123000000000.0,"treasuryStock":-27334000000.0,"valuationAndConversionAdjustments":4773000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":18453000000.0,"costOfSales":8177000000.0,"grossProfit":10275000000.0,"sgaExpenses":5854000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":1865000000.0,"operatingIncome":4421000000.0,"nonOperatingIncome":250000000.0,"nonOperatingExpenses":11000000.0,"interestExpense":4000000.0,"ordinaryProfit":4660000000.0,"extraordinaryGain":0.0,"extraordinaryLoss":4000000.0,"incomeBeforeTax":4655000000.0,"incomeTaxes":1292000000.0,"netIncome":3362000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3362000000.0,"comprehensiveIncome":3297000000.0,"eps":87.78,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/8\/12","stockCode":4521,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2021\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":16012000.0,"sharesOwendPercent":0.423,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.835,"cashAndCashEquivalents":76270000000.0,"assets":165591000000.0,"currentAssets":114868000000.0,"fixedAsset":50723000000.0,"tangibleFixedAssets":25548000000.0,"intangibleFixedAssets":674000000.0,"investmentAndOtherAssets":24499000000.0,"liabilities":27260000000.0,"currentLiabilities":21272000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5988000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":138330000000.0,"capitalStock":132906000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":126359000000.0,"treasuryStock":-28712000000.0,"valuationAndConversionAdjustments":5424000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":37588000000.0,"costOfSales":16588000000.0,"grossProfit":20999000000.0,"sgaExpenses":11963000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":4008000000.0,"operatingIncome":9036000000.0,"nonOperatingIncome":278000000.0,"nonOperatingExpenses":23000000.0,"interestExpense":8000000.0,"ordinaryProfit":9290000000.0,"extraordinaryGain":195000000.0,"extraordinaryLoss":49000000.0,"incomeBeforeTax":9436000000.0,"incomeTaxes":2714000000.0,"netIncome":6721000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":6721000000.0,"comprehensiveIncome":7306000000.0,"eps":176.24,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":5434000000.0,"depreciationAndCashflowFromOperatingActivities":1230000000.0,"cashFlowFromInvestingActivities":-1182000000.0,"cashFlowFromFinancialActivities":-5287000000.0,"changesInCashAndCashEquivalents":-1035000000.0,"列1":"q2r","submitDate":"2021\/11\/11","stockCode":4521,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0},{"edinetCode":"E00935","endDate":"2021\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.83,"cashAndCashEquivalents":null,"assets":167677000000.0,"currentAssets":111519000000.0,"fixedAsset":56157000000.0,"tangibleFixedAssets":25704000000.0,"intangibleFixedAssets":6020000000.0,"investmentAndOtherAssets":24432000000.0,"liabilities":27984000000.0,"currentLiabilities":22073000000.0,"shorTermDept":3850000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":5911000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":139692000000.0,"capitalStock":133590000000.0,"capital":23853000000.0,"capitalSurplus":11406000000.0,"accumulatedEarnings":127044000000.0,"treasuryStock":-28713000000.0,"valuationAndConversionAdjustments":5523000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":57708000000.0,"costOfSales":25689000000.0,"grossProfit":32019000000.0,"sgaExpenses":18129000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":6035000000.0,"operatingIncome":13889000000.0,"nonOperatingIncome":477000000.0,"nonOperatingExpenses":44000000.0,"interestExpense":12000000.0,"ordinaryProfit":14322000000.0,"extraordinaryGain":195000000.0,"extraordinaryLoss":60000000.0,"incomeBeforeTax":14457000000.0,"incomeTaxes":4211000000.0,"netIncome":10246000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":10246000000.0,"comprehensiveIncome":10930000000.0,"eps":269.41,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2022\/2\/10","stockCode":4521,"accountingYear":null,"accountingYearStart":"2021\/4\/1","accountingYearEnd":"2022\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E00935","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":23853,"settlementDate":"2022\/3\/31","submitterName":"科研製薬株式会社","submitterNameEnglish":"KAKEN PHARMACEUTIAL CO., LTD.","submitterNameKana":"カケンセイヤクカブシキガイシャ","location":"文京区本駒込二丁目２８番８号","industory":"医薬品","corporateNumber":4010000000000.0}]